Source: BioPharma-Reporter

Cytena: ExcellGene and Cytena team up to optimize workflows for mAb and therapeutic protein manufacturing

ExcellGene SA, a Swiss biologics focused CDMO, has established a collaboration agreement with German biological cell instrument developer, Cytena.

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Jonas Schoendube's photo - CEO of Cytena

CEO

Jonas Schoendube

CEO Approval Rating

87/100

Read more